Affimed (NASDAQ:AFMD) will be posting its quarterly earnings results before the market opens on Wednesday, May 22nd. Analysts expect Affimed to post earnings of ($0.16) per share for the quarter.
Affimed (NASDAQ:AFMD) last posted its earnings results on Wednesday, March 27th. The biopharmaceutical company reported $0.17 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.17) by $0.34. Affimed had a negative return on equity of 44.56% and a negative net margin of 87.00%. The business had revenue of $25.96 million during the quarter. On average, analysts expect Affimed to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.
Affimed stock opened at $3.37 on Monday. Affimed has a 52 week low of $1.40 and a 52 week high of $7.35. The company has a debt-to-equity ratio of 0.04, a current ratio of 3.01 and a quick ratio of 3.00. The stock has a market cap of $210.25 million, a P/E ratio of -8.87 and a beta of 3.23.
A hedge fund recently raised its stake in Affimed stock. Geode Capital Management LLC grew its position in shares of Affimed NV (NASDAQ:AFMD) by 29.0% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 66,074 shares of the biopharmaceutical company’s stock after purchasing an additional 14,854 shares during the period. Geode Capital Management LLC owned about 0.11% of Affimed worth $205,000 at the end of the most recent reporting period. 41.10% of the stock is currently owned by hedge funds and other institutional investors.
Several equities analysts recently commented on the company. Leerink Swann assumed coverage on Affimed in a research report on Thursday, March 28th. They set an “outperform” rating and a $4.17 target price for the company. ValuEngine cut Affimed from a “buy” rating to a “hold” rating in a research report on Friday, March 29th. Zacks Investment Research upgraded Affimed from a “hold” rating to a “strong-buy” rating and set a $4.75 target price for the company in a research report on Friday, March 29th. Finally, Svb Leerink assumed coverage on Affimed in a research report on Thursday, March 28th. They set an “outperform” rating and a $8.00 target price for the company. Two equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average price target of $4.99.
TRADEMARK VIOLATION NOTICE: “Affimed (AFMD) to Release Earnings on Wednesday” was posted by Enterprise Leader and is the property of of Enterprise Leader. If you are reading this report on another site, it was stolen and republished in violation of international trademark and copyright legislation. The legal version of this report can be read at https://theenterpriseleader.com/2019/05/20/affimed-afmd-to-release-earnings-on-wednesday.html.
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Europe, and Germany. Its lead product candidate is AFM13, a natural killer cell (NK-cell) TandAb, which is in Phase 2a clinical study of relapsed CD30-positive lymphoma and Phase 1b clinical study of anti-PD-1 antibody Keytruda (pembrolizumab) in patients with relapsed Hodgkin lymphoma.
Receive News & Ratings for Affimed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Affimed and related companies with MarketBeat.com's FREE daily email newsletter.